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Background: Children who take methotrexate for juvenile idiopathic arthritis may experience side effects, including
nausea and vomiting, leading to anticipatory nausea in some children, and fear of injections or blood tests. The aim
of this study was to examine the prevalence and extent of these difficulties and their impact on quality of life.
Methods: Participants were mothers of children with JIA who were currently taking methotrexate (MTX). Mothers
completed a questionnaire about MTX that was developed for the study, two questions from the treatment subscale
of the Pediatric Quality of Life Inventory (PedsQL) Rheumatology scale to assess needle-related problems and the Child
Health Questionnaire 50-item parent version (CHQ-PF50) to assess health-related quality of life (HRQoL).
Results: 171 mothers participated in the study. More than half of children were reported to have experienced one or
more of: nausea or vomiting after taking MTX, anticipatory nausea, fear of blood tests or fear of injections. There was no
significant difference in reported rates of sickness or needle-related problems between MTX responders (ACR70 or
above), partial responders (ACR30 or ACR50) and non-responders. In multivariate analyses, variables that were significant
independent predictors of one or more MTX-related difficulties included younger age, taking MTX subcutaneously and
having a larger number of currently active joints. Feeling sick after taking MTX was a significant independent predictor of
poorer scores on the physical summary scale of the CHQ-PF50. Anxiety about injections and feeling sick after taking MTX
were significant independent predictors of poorer scores on the psychosocial summary scale.
Conclusions: Difficulties in taking MTX are experienced by a significant proportion of children with JIA and these may
have an adverse impact on HRQoL. Approaches to help minimize these difficulties are required.
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Methotrexate (MTX) is the first choice disease-modifying
antirheumatic drug (DMARD) for the treatment of Juvenile
Idiopathic Arthritis (JIA) [1,2]. Along with proven efficacy
in reducing arthritis, both physical and psychosocial quality
of life (QoL) have also been found to improve in children
with JIA treated with MTX [3]. Notwithstanding these* Correspondence: Stanton.Newman.1@city.ac.uk
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reproduction in any medium, provided the orbenefits, some children experience difficulties related to
taking MTX. The most common recognised side effects are
gastrointestinal, including nausea and vomiting [4,5]. The
use of folic acid or folinic acid has been suggested to reduce
such side effects [6], although little formal evidence base
for this is yet available. If a child experiences nausea or
vomiting after taking MTX, anticipatory nausea (symptoms
occurring before medication is taken), and reluctance to
take MTX may develop [5,7]. Further problems can arise as
a result of fear of injections or the monthly monitoring
blood tests that are necessary while taking MTX.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recognised [7], the extent to which they may impact on
adherence to the medication and on the child’s quality of
life is less clear. We are not aware of any study that
has systematically examined the relationship between
MTX-related problems and quality of life. As parents
are key facilitators in their child’s medication regime
[8], it is also important to gain an insight into parents’
views of MTX and whether any difficulties their child
experiences in taking MTX affects their willingness to
allow their child to try other medications that may be
prescribed in the future. The Sport Aiding Medical
Research for Kids (SPARKS) Childhood Arthritis Response
to Medication Study (CHARMS) [9,10] aims to define the
factors that influence the response of children with JIA to
methotrexate. As part of the study we investigated the
difficulties arising from the use of MTX for JIA. This paper
reports data collected from mothers of children with JIA
about the extent of MTX-related difficulties experienced by
their children and factors associated with these difficulties.
We also examined how MTX-related difficulties impact on
reported adherence, the children’s quality of life and
mothers’ views about MTX. Finally, we examined whether
there was any difference between responders and non-
responders [11] in MTX-related difficulties or mothers’
views about MTX.Methods
Participants were recruited as part of the SPARKS Child-
hood Arthritis Response to Medication Study (SPARKS-
CHARMS), which examines genetic, immunobiological
and psychological aspects of response to MTX or anti-
TNF therapy given for arthritis [9,10,12,13]. The study
recruits children of any age with juvenile idiopathic arthritis
(JIA), defined by ILAR criteria [14], who are under the care
of the Rheumatology service at Great Ormond Street
Hospital for Children (GOSH) or the Adolescent Rheuma-
tology service at University College Hospital, London, UK.
The practice in these two centres is that children start
on a MTX dose equivalent to 15 mg per metre squared
(as per evidence of efficacy [15]). In those who respond
very well, the dose may not be increased as the child
grows i.e. actual dose falls; in some children, the dose
is increased with growth to maintain the 15 mg per
metre square dose. The practice in these two centres is
to offer folic acid from the start to all children taking
MTX (1mg per day as syrup or in some cases 5mg
per week). The practice for nausea is to offer and en-
courage use of anti-emetics, typically Ondansetron, to
be used pre and post MTX as required. The practice
with route is that for those who start on oral and de-
velop regular nausea, many are offered the change to
subcutaneous.Children were recruited to the main study if they: a)
were about to start taking MTX or anti-TNF, b) were
currently taking MTX or, c) had taken MTX in the past.
For the psychological part of the study, we aimed
to recruit the parent(s) of 230 children. Parents
whose children were aged up to sixteen years, plus
children aged five to sixteen years were asked to complete
questionnaires about experiences of taking MTX and
HRQoL. Recruitment was restricted to English-speakers
because the questionnaire was available only in English (this
was not a restriction in the main study). Parents were given
the questionnaires to complete in the clinic but they could
choose to take them home and return them by post. The
aim was to recruit at least one parent but if both parents
attended the clinic they were both invited to participate.
Although fathers and the patients themselves participated
in the study, mothers were the largest respondent group.
We have previously shown that there can be high levels of
discordance between mothers’ and fathers’ views about
their child’s JIA [9], and others have reported discordance
between parent and child reports [16], so to help ensure
consistency we have limited this analysis to reports from
one parent (mothers). This analysis is restricted to mothers
of those children in the study who had taken MTX for at
least six months, and were still taking it at the time the
questionnaires were completed.
The study had full ethical approval from the Institute of
Child Health/GOSH Local Research Ethics Committee,
and all participants gave full, informed written consent
(parental consent and age appropriate child/young person
assent). The study conforms to the principles outlined in
the Declaration of Helsinki.
Study questionnaires
A questionnaire on the experience of taking MTX was
developed for the study as there was no appropriate
questionnaire available on this topic. The questionnaire
asked how frequently the child a) felt sick before taking
MTX; b) felt sick after taking MTX; c) vomited after
taking MTX. Response options were: never/hardly ever,
less than once a month, about once a month, two or
three times a month, every week. The questionnaire also
asked about how frequently a dose of MTX was missed
(1 item), and mothers’ views of MTX (4 items). The
experience of needle-related problems was assessed with
two questions from the treatment subscale of the Pediatric
Quality of Life Inventory (PedsQL) Rheumatology scale
[17]. The questions asked how much of a problem anxiety
about injections and about blood tests have been in the
past month. Response options were: never, almost never,
sometimes, often, almost always.
Adherence was estimated by the reported frequency a
dose of MTX was missed for any reason. Response options
were: never/hardly ever, less than once a month, about
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Missing a dose about once a month or more frequently
was classified as non-adherence. This cut-off was used as it
would represent an adherence rate of almost 80%, which is
a conventional cut-off used in adherence research [18].
To capture their views on taking other medications,
mothers were also asked how willing they would be for
their child to try other arthritis medications prescribed in
the future. This was assessed with a 100mm visual
analogue scale (VAS) from ‘not willing’ (0) to ‘very willing’
(100).
Health-related quality of life (HRQoL) was assessed
with the British version of the Child Health Questionnaire
50-item parent version (CHQ-PF50) [19], which has been
validated for use in children with JIA [20]. This measure
provides two standardised norm-based summary scores – a
physical summary score (PhS) and psychosocial summary
score (PsS) – which each range from 0 – 100, have a mean
of 50 and standard deviation of 10. Higher scores indicate a
better quality of life.
Data on child’s age, gender, JIA category disease dur-
ation, MTX route, duration of use and dose, and MTX
responder status, (assessed using the core set criteria
and internationally agreed definition of improvement
[11]) were also collected. Current disease severity was
assessed by the number of limited and inflamed joints.
Data on mother’s age and education were collected.n
Insufficient English 7
Refused 2
Did not return questionnaire 28
Children who had take
one parent invited to c
Questionnaire complete
Mother only, n = 136
Father only, n = 21
Both parents, n = 86
Mothers completed ps
Cases excluded becau
Child not currently tak
Total number of mothe
Figure 1 Recruitment flowchart.Statistical analysis
Statistical analyses were conducted in SPSS Statistics 21.
To examine potential risk factors for MTX problems we
examined the association between occurrence of each
problem (sickness before taking, sickness after taking,
vomiting after taking, anxiety about injections, anxiety
about blood tests) with age, gender, current disease severity,
duration of MTX use, route of MTX administration
(oral or subcutaneous), current MTX dose and
whether or not the child was taking folic acid, using
binary logistic regression analyses. A problem was
categorised as being present if it occurred frequently
i.e. response options two or three times a month/every
week (sickness-related questions) or often/almost always
(needle-related problems).
The potential impact of MTX-related difficulties on
adherence was analysed using Fishers Exact Tests to
compare those classified as adherent or non-adherent on
their likelihood of having experienced problems.
To examine which of the MTX experiences accounted
for most variance in HRQoL measured with the CHQ-PF50
, the independent variables were included in hierarchical
multiple regressions using stepwise method. Two regres-
sions were performed: one analysis examined the physical
and the other the psychosocial summary scores of the
CHQ-PF50. The independent variables were entered
into the regression in blocks in the following order:n MTX for ≥6 months for JIA.  At least 
omplete psychology questionnaire 
n = 280
d by at least one parent, n= 243(87%)
ychology questionnaire                        222
se of incomplete data 9
ing MTX 42
rs included in paper 171
Table 1 Sample characteristics of patients and
respondents
Children’s characteristics
n 171
Gender, n (%) female 123 (71.9)
Age in years when questionnaire data completed, mean (S.
D.)
9.0 (4.1)
JIA category, n (%)
Systemic 26 (15.2)
Oligo persistent 13 (7.6)
Oligo extended 42 (24.6)
Poly RF – 63 (36.8)
Poly RF + 9 (5.3)
Poly, RF status unknown 2 (1.2)
Psoriatic 6 (3.5)
ERA 10 (5.8)
Disease duration in years, mean (S.D.) (n=169) 4.0 (3.3)
Responder status (known for n = 117)
Non-responder 34 (29.1)
ACR30 83 (70.9)
ACR50 74 (63.2)
ACR70 59 (50.4)
Current disease severity, median, range, (IQR)
Number of active joints (known for n = 158) 0, 0–12, 0-
1
Number of limited joints (known for n = 155) 0, 0–32, 0-
2
Mothers’ characteristics
Age in years, mean (S.D.) 38.5 (6.7)
Education*, n (%)
≤GCSE or equivalent 105 (63.2)
Advanced level or equivalent 23 (13.8)
Degree/Postgraduate 38 (22.9)
Not stated 5
*Advanced level – national examinations usually taken at age 18, required for
university admission.
GCSE – national examinations usually taken at age 16.
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by which MTX taken, duration of MTX use, current
dose; 4. MTX problems. This order was used because it
enables examination to be made as to whether experience
of MTX added to the explanation of quality of life once
disease severity had been taken into account.
To examine whether experience of MTX-related
problems affected mothers’ ratings of MTX and willingness
to allow their child to take other medications, t-tests were
conducted comparing those who rarely/never experienced
each problem with those who had experienced it. To
examine the relationship between current disease severity
and mothers’ ratings of MTX, Spearman rho correlations
were conducted.
To compare responders, partial responders and
non-responders on experience of MTX-related difficulties
and mothers’ views of MTX, we conducted χ2 tests and
analyses of variance (ANOVA) respectively.
Results
A recruitment flowchart is shown in Figure 1. The parents
of 280 children who had taken MTX for ≥6 months were
approached to take part in the psychological part of the
study. Of these, a questionnaire was completed by at least
one parent of 243 (87%) children. Mothers of 222 children
completed questionnaires but 9 were excluded from this
analysis because of large amounts of missing data. A
further 42 are not included in this analysis because their
child was not taking MTX at the time the questionnaire
was completed. Data for this paper were thus provided by
171 mothers. Demographic data of the 171 children and
their mothers are shown in Table 1. As expected in JIA,
the children were predominantly female (71.9%). The
distribution among JIA categories was also as expected for
use of MTX in JIA, with polyarticular rheumatoid factor
negative (RF-) JIA being the largest group (36.8%) and
extended oligoarticular the next largest (24.6%). Of those
for whom response to MTX [11] was known, 50.4% were
classified as good responders, that is they achieved
improvement at ACR70 level or better, which is also
in line with expectations.
The majority of children (n = 100, 58.5%) were currently
taking MTX subcutaneously but most of these (n = 76)
had previously taken it orally. Table 2 shows the numbers
who have moved from oral administration to subcutaneous
and vice versa during their time taking MTX.
Extent of methotrexate-related problems
The extent of MTX-related problems, including nausea
and/or vomiting, before or after the weekly MTX treat-
ment, and fear of needles, is shown in Figure 2. More than
half of the children were reported to have experienced one
or more of these difficulties. Almost a third of children
were reported to feel sick every week after taking MTX andalmost a quarter experienced weekly anticipatory nausea.
Fifteen per cent of children were reported to have vomited
every week after taking MTX. Fear of injections and/or
blood tests rated as often or almost always was reported in
over a third of children with over half reported as experien-
cing them at least sometimes.
Potential ‘risk factors’ for methotrexate-related problems
Univariate and multivariate logistic regression analyses of
factors associated with MTX-related problems are shown
in Table 3. A variety of parameters were associated with
MTX-related problems. In univariate analyses, feeling sick
Table 2 Methotrexate history of study patients
Age in years at starting MTX, mean (S.D.) (n=168) 6.1 (3.9)
Duration in months of MTX use, median (IQR) 29.0 (11.5 – 60.5)
Current MTX dose (mg/m2/week), median (IQR) 12.5 (10 – 15)
MTX route, n (%)
Oral route throughout 55 (32.2)
Current route oral but previously subcutaneous 16 (9.4)
Subcutaneous route throughout 24 (14.0)
Current route subcutaneous but previously oral 76 (44.4)
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older age, larger current MTX dose and longer duration
of taking MTX. Subcutaneous route and higher current
disease activity also significantly increased risk of feeling
feeling sick before MTX. Vomiting after taking MTX was
significantly related to subcutaneous route and longer dur-
ation of taking MTX. Anxiety about blood tests was sig-
nificantly related to younger age and shorter duration
of MTX use. Anxiety about injections was signifi-
cantly related to younger age, subcutaneous route and
higher current disease activity. When these risk factors
were simultaneously entered into logistic regression
models, age, MTX route and current disease activity0
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Figure 2 Frequency of mothers’ reports of their children's methotrexaremained significant independent predictors of one or
more of the problems. Fear of blood tests and injections
decreased with age. Children who were taking MTX sub-
cutaneously were more likely to vomit after taking it than
children who were taking MTX orally (see also Figure 3).
Anxiety about injections was also more common in those
taking MTX subcutaneously. Those with a larger number
of currently active joints were more likely to feel sick be-
fore taking MTX and to be anxious about injections. Gen-
der, number of limited joints and whether or not the child
was taking folic acid were not related to any of the MTX-
related difficulties in univariate or multivariate analyses.
The relationship between methotrexate experiences and
adherence
The rate of reported adherence was very high, with
only seven children (4.1%) classified as non-adherent.
Fisher’s Exact Tests showed no significant differences
in adherence between those who had MTX-related
problems and those who did not.
Mothers’ views about methotrexate and about treatment
in general
In response to the questions, ‘How do you rate metho-
trexate overall?’ and ‘Are you satisfied with the effects ofafter Anxious about
blood tests
Anxious about
injections
d
c
b
a
/injections:
ys
te-related sickness and needle-related fear.
Table 3 Multivariate logistic regression models of risk factors for MTX-related difficulties
Potential risk
factors
MTX problems
Feel sick before taking MTX Feel sick after taking MTX Vomit after taking MTX Anxious about blood tests Anxious about injections
n Unadjusted
Exp(β) (95% CI)
Adjusted Exp
(β) † (95% CI)
Unadjusted
Exp(β) (95% CI)
Adjusted Exp
(β) † (95% CI)
Unadjusted
Exp(β) (95% CI)
Adjusted Exp
(β) † (95% CI)
Unadjusted
Exp(β) (95% CI)
Adjusted Exp
(β) † (95% CI)
Unadjusted
Exp(β) (95% CI)
Adjusted Exp
(β) † (95% CI)
Age 171 1.10 (1.01–1.19) 1.06 (0.92–1.22) 1.15 (1.06–1.24) 1.11 (0.98–1.25) 1.06 (0.97–1.17) 1.07 (0.92–1.24) 0.82 (0.75–0.90) 0.76 (0.65-0.89) 0.85 (0.79–0.93) 0.83 (0.73–0.95)
Sex
Male 48 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Female 123 0.56 0.89 1.06 1.38 0.52 0.48 1.18 0.87 0.79 0.78
(0.28–1.15) (0.37–2.16) (0.54–2.08) (0.62–3.09) (0.24–1.16) (0.19–1.25) (0.58–2.42) (0.35-2.18) (0.40–1.55) (0.32–1.88)
MTX current
route
Oral 71 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Subcutaneous 100 2.51 2.33 1.39 1.50 3.21 3.75 1.25 0.79 2.40 2.31
(1.21–5.19) (0.96–5.66) (0.75–2.58) (0.69–3.26) (1.31–7.89) (1.28–11.06) (0.66–2.40) (0.34-1.87) (1.27–4.54) (1.02–5.22)
MTX current
dose (mg)
171 1.10 1.06 1.11 1.06 1.05 0.98 0.95 1.10 0.96 1.03
(1.02–1.19) (0.95–1.19) (1.04–1.20) (0.96–1.17) (0.97–1.14) (0.88–1.10) (0.88–1.02) (0.97-1.25) (0.89–1.02) (0.93–1.15)
Duration of MTX
use in months
168 1.02 1.01 1.01 1.01 1.02 1.01 0.98 0.996 0.995 1.00
(1.01 - 1.03) (0.99-1.03) (1.00- 1.03) (0.99-1.02) (1.00 -1.03) (0.99-1.03) (0.97-0.997) (0.98-1.01) (0.98 - 1.01) (0.98 - 1.01)
Taking folic acid
No 24 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Yes 124 0.41 0.55 0.48 0.68 0.41 0.57 1.02 0.98 0.76 0.42
(0.17 – 1.01) (0.19 – 1.58) (0.20 – 1.17) (0.25 – 1.85) (0.16 – 1.08) (0.18 – 1.76) (0.41 – 2.59) (0.32 - 3.03) (0.27 – 1.60) (0.14 – 1.25)
Current disease
severity:
No. active joints 158 1.24 1.29 1.07 1.09 1.07 0.91 1.20 1.15 1.23 1.40
(1.06 – 1.44) (1.05 – 1.60) (0.92 – 1.23) (0.91 – 1.30) (0.91 – 1.25) (0.74 – 1.13) (0.97 – 1.29) (0.95 - 1.40) (1.03 – 1.46) (1.09 – 1.79)
No. limited joints 155 1.09 1.01 1.01 0.95 1.09 1.04 0.97 0.97 0.98 0.93
(0.99 – 1.20) (0.91 – 1.12) (0.92 – 1.10) (0.85 – 1.06) (0.99 – 1.21) (0.92 – 1.17) (0.88 – 1.08) (0.85 - 1.10) (0.90 – 1.07) (0.82 – 1.06)
†Adjusted for all variables simultaneously.
Exp(β) – predicted change in odds for a one unit increase in the predictor variable.
Statistically significant findings in the adjusted analyses are shown in bold.
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Figure 3 Comparison between oral and subcutaneous administration on experience of MTX-related difficulties.
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111/168 (66.1%) rating it as very good or excellent and
130/170 (76.5%) being mostly or completely satisfied
with its effects (Additional file 1: Table S1).
A comparison of mothers’ ratings of MTX between
those with and without MTX-related difficulties is
shown in Additional file 2: Table S2. Mothers’ rating of
the severity of side effects compared to their expectations
was worse in those who reported sickness before or after
or vomiting after taking MTX. No differences were found
between those reporting or not reporting MTX-related
difficulties in mothers’ ratings of effectiveness, satisfaction
with effects, feeling their child received the right
medication for them, overall rating of MTX, or willingness
to allow their child to take future medications.
There was a small but statistically significant negative
correlation between the number of currently active joints
(that is, active at the time the questionnaire was completed)
and mothers’ satisfaction with MTX. There were also small
but statistically significant negative correlations between
the number of limited joints and mothers’ rating of
the effectiveness of MTX and their overall rating of
MTX (Additional file 3: Table S3).
Relationship with responder status
Responder status [11] after the first 6 months of taking
MTX was known for 117 (68.4%) children (Table 1).
Core set criteria for response to MTX variables were not
always available because data were collected retrospectively,
sometimes several years after the child first started taking
MTX. Not all children were first prescribed MTX at the
study hospital therefore core outcome variables before and
six months after taking MTX for the first time were
not necessarily available. The duration since first pre-
scribed MTX was significantly longer in those for
whom responder status was unknown (mean years 4.0
(S.D. 2.4) v. 1.5 (2.0), t = 6.93, df = 166, p < 0.0005).We did not find any statistically significant differences
between responder status known or unknown on age,
gender, JIA category, HRQoL or any of the MTX
experiences.
In those for whom responder status was known
(n = 117), there were no significant differences between
responders and partial- or non-responders in reported
sickness or needle-related problems or in mothers’ ratings
of MTX (Additional file 4: Table S4).
Relationship between methotrexate-related problems and
children’s quality of life
The mean (S.D.) score of 40.4 (14.2) on the physical sum-
mary score of the CHQ-PF50 is approximately 1 S.D.
below population norms whereas the respective score of
47.3 (12.1) on the psychosocial summary score is closer
to the norm.
Multivariate analyses of the relation between experiences
of MTX and the physical and psychosocial summary scales
of the CHQ-PF50 are shown in Table 4.
In addition to the number of limited joints, feeling sick
after taking MTX was a significant independent predictor
of poorer scores on the physical summary scale of the
CHQ-PF50, after controlling for demographic variables,
disease severity, MTX dose, duration of use and administra-
tion method. Anxiety about blood tests and feeling sick
after taking MTX were significant independent predictors
of poorer scores on the psychosocial summary scale.
Overall, variables in the models accounted for 30.5%
of variance in the physical summary score and 9.7%
of the variance in the psychosocial summary score.
Discussion
Key findings of this study are that over half of children
taking MTX for JIA were reported to experience some
difficulty. Reports of nausea before and after taking
MTX were more common in children whose method of
Table 4 Stepwise multiple regression analysis of variables
related to health-related quality of life
Model B S.E. β P R2
Physical summary score
1 age -.583 .284 -.168 .042 .028
2 age -.463 .268 -.134 .086 .150
Number of limited joints -1.340 .296 -.350 .000
3 age -.475 .265 -.137 .075 .176
Number of limited joints -1.145 .306 -.299 .000
Number of active joints -1.094 .510 -.170 .034
4 age -.586 .263 -.169 .027 .214
Number of limited joints -1.058 .302 -.276 .001
Number of active joints -1.064 .500 -.166 .035
MTX administration route -5.691 2.181 -.198 .010
5 age -.200 .325 -.058 .539 .235
Number of limited joints -1.023 .299 -.267 .001
Number of active joints -1.002 .496 -.156 .045
MTX administration route -4.756 2.210 -.165 .033
MTX current weekly dose -.572 .289 -.185 .050
6 age .023 .317 .007 .941 .305
Number of limited joints -1.084 .287 -.283 .000
Number of active joints -.874 .476 -.136 .068
MTX administration route -3.892 2.126 -.135 .069
MTX current weekly dose -.495 .277 -.160 .077
feel sick after taking MTX -7.951 2.121 -.278 .000
Psychosocial summary score
1 feel sick after taking MTX -5.624 1.976 -.230 .005 .053
2 feel sick after taking MTX -5.338 1.940 -.218 .007 .097
anxious about blood tests -5.347 2.027 -.209 .009
Variables entered into the models:
Block 1: age, sex.
Block 2: age, sex, number of active joints, number of limited joints.
Block 3: age, sex, number of active joints, number of limited joints, MTX
administration route, duration of MTX use, MTX current dose.
Block 4: age, sex, number of active joints, number of limited joints, MTX
administration route, duration of MTX use, MTX current dose, feel sick before
taking MTX, feel sick after taking MTX, vomit after taking MTX, anxious about
blood tests, anxious about injections.
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sick after taking MTX and anxiety about blood tests were
independent predictors of poorer quality of life. Finally, in
spite of these difficulties, the majority of mothers rated
MTX positively overall.
It is well known to clinicians that children who take
MTX for JIA may experience the problems reported
here [5] but we are aware of only one other study
that has systematically documented the extent of
these problems [21], however that study did not
examine the relationship with quality of life. Bulatović
et al. [21] found that just over half of children had‘MTX intolerance’ so the findings of our current
study are consistent with that research. Although the
benefits of MTX for treating JIA are well known [2],
it is also important to recognise and take all possible
steps to minimise such difficulties. These strategies may
include anti-emetic medication, and support from spe-
cialist nurses or psychologists. A small study of behav-
ioural therapy (systemic desensitization or cognitive
behavioural therapy) for children with JIA having nausea
suggests that this can be beneficial [7].
Our study found that taking MTX subcutaneously was
associated with a greater risk of post-administration
vomiting. As the subcutaneous route has been suggested
to be advantageous for treatment efficacy of MTX
[22,23] new approaches to managing the difficulties in
taking MTX subcutaneously could provide an important
addition in JIA treatment.
The findings of this study have important clinical
implications. The impact of problems in taking MTX on
quality of life emphasise that such difficulties have a
wider impact, and this highlights the importance of
looking for ways of minimising the difficulties and
distress in taking MTX. Currently, psychological input is
usually reserved for those who report significant
problems in dealing with JIA and a pilot study has shown
the potential benefits of such an approach [7]. However,
many parents may value advice on how to manage the dis-
tress their children experience in taking MTX. Anticipatory
nausea is a good example of a conditioned response and
psychological techniques have a good history of treating
such responses [24]. There is a large literature on how to
enhance self-management of chronic illness [25-28] and
extending this approach to JIA may prove beneficial.
Our findings suggest that for children with JIA, difficulties
in taking MTX are not necessarily explained by whether the
child’s arthritis does or does not improve as a result of
taking MTX. Mothers valued MTX as a treatment and were
satisfied with the treatment decisions made in spite of the
reported difficulties experienced. This is an important
finding as it indicates that mothers appreciated the
medication despite the problems experienced, and
suggests that their experience is unlikely to have an
on-going impact on their attitudes to medication.
There are several limitations to our study. The data
presented were collected from proxy respondents, in this
case the mothers of children with JIA, and patients and
proxy respondents are known to differ in their evaluations
[16]. However, approximately 39% of the children were
aged under eight years and may have been unable to
provide all of the self-report data for the study. We
considered it important to be able to examine the
experience of taking MTX for young children and
caregiver ratings are widely used in assessment in JIA [11].
The study of MTX intolerance by Bulatovic et al. [17]
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therefore proxy respondents were also presumably included
in that study.
We did not have information on the responder status of
all children because these data were collected retrospect-
ively. However, there were no differences in responses
about treatment between those for whom responder status
was known and those where it was unknown.
Data about problems related to taking MTX orally or
subcutaneously are complicated by the fact that many
children may change from oral to subcutaneous admin-
istration during the course of taking the medication.
This will be the case in any study that includes children
who have been taking MTX for some time. It would be
of interest for future research to collect information
about side effects and perceptions of MTX from the
time of first prescription and to monitor how these alter
over time and with changes in method of administration.
It would also be of interest to examine how the
occurrence of other adverse events, for example a
raised alanine aminotransferase (ALT) test result,
would influence findings; we did not have blood test result
data to examine this question. The findings reported here
are based on cross-sectional data therefore, as with all
such data, we cannot infer causal direction.
Conclusions
In conclusion, our study suggests that difficulties in taking
MTX for children with JIA are common, and not
explained simply by the child’s clinical response to the
medication. These difficulties can have an adverse effect
on the child’s HRQoL and approaches to help minimize
and overcome them are required.
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